Table 2:
Demographics and clinicopathological characteristics of the cohort by Stage, analysis based on chi-squared tests for SRCBC Stage I-IV patients, National Cancer Data Base (NCDB), 2004-2016 (n=324)
| Variable | Stage 1 | Stage 2 | Stage 3 | Stage 4 | p-value |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | ||
| 63 (19.4) | 85 (26.2) | 64 (19.8) | 112 (34.6) | ||
| Age (years) | |||||
| <50 | 5 (7.9) | 11 (12.9) | 8 (12.5) | 14 (12.5) | 0.46 |
| 50-59 | 12 (19.0) | 12 (14.1) | 14 (21.9) | 30 (26.8) | |
| 60-69 | 24 (38.1) | 30 (35.3) | 25 (39.1) | 30 (26.8) | |
| ≥70 | 22 (34.9) | 32 (37.6) | 17 (26.5) | 38 (33.9) | |
| Gender | |||||
| Male | 1 (1.6) | 1 (1.2) | 0 | 3 (2.7) | 0.87a |
| Female | 62 (98.4) | 84 (98.8) | 64 (100) | 109 (97.3) | |
| Race | |||||
| White | 52 (82.5) | 65 (76.5) | 49 (76.5) | 78 (69.6) | |
| Black | 3 (4.8) | 7 (8.2) | 2 (3.1) | 13 (11.6) | 0.31 |
| Hispanic | 6 (9.5) | 6 (7.1) | 7 (10.9) | 7 (6.3) | |
| Other | 2 (3.2) | 7 (8.2) | 6 (9.4) | 14 (12.5) | |
| CDS | |||||
| 0 | 52 (82.5) | 64 (75.3) | 56 (87.5) | 96 (85.7) | |
| 1 | 8 (12.7) | 17 (20.0) | 7 (10.9) | 10 (8.9) | 0.65a |
| 2 | 3 (4.8) | 3 (3.5) | 1 (1.6) | 4 (3.6) | |
| ≥3 | 0 (0) | 1 (1.2) | 0 (0) | 2 (1.8) | |
| Insurance | |||||
| None | 0 | 1 (1.2) | 1 (1.6) | 5 (4.5) | |
| Private | 24 (38.1) | 27 (31.8) | 31 (48.4) | 42 (37.5) | |
| Medicaid | 2 (3.2) | 4 (4.7) | 3 (4.7) | 8 (7.1) | 0.49a |
| Medicare | 31 (49.2) | 46 (54.1) | 22 (34.4) | 51 (45.5) | |
| Other | 6 (9.5) | 7 (8.2) | 7 (10.9) | 6 (5.4) | |
| Treating Facility Geographic Region | |||||
| New England | 3 (4.8) | 7 (8.2) | 7 (10.9) | 7 (6.3) | |
| Mid-Atlantic | 13 (20.6) | 21 (24.7) | 12 (18.8) | 21 (18.8) | |
| South Atlantic | 7 (11.1) | 15 (17.6) | 11 (17.2) | 15 (13.4) | |
| East North Central | 12 (19.0) | 16 (18.8) | 10 (15.6) | 27 (24.1) | |
| East South Central | 2 (3.2) | 1 (1.2) | 3 (4.7) | 10 (8.9) | 0.49a |
| West North Central | 6 (9.5) | 1 (1.2) | 4 (6.3) | 4 (3.6) | |
| West South Central | 10 (15.9) | 11 (12.9) | 8 (12.5) | 11 (9.8) | |
| Mountain | 2 (3.2) | 3 (3.5) | 5 (7.8) | 4 (3.6) | |
| Pacific | 8 (12.7) | 10 (11.8) | 4 (6.3) | 11 (9.8) | |
| Facility Type | |||||
| Community | 5 (7.9) | 10 (11.8) | 5 (7.8) | 14 (12.5) | |
| CCC | 25 (39.7) | 28 (32.9) | 28 (43.8) | 36 (32.1) | |
| Academic | 23 (36.5) | 32 (37.6) | 22 (34.4) | 39 (34.8) | 0.90a |
| INCC | 10 (15.9) | 15 (17.6) | 9 (14.0) | 21 (18.8) | |
| Unknown | 0 | 0 | 0 | 2 (1.8) | |
| Tumor Size (cm) | |||||
| ≤ 2 | 60 (95.2) | 19 (22.4) | 7 (10.9) | 14 (12.5) | |
| >2 - 5 | 1 (1.6) | 56 (65.9) | 24 (37.5) | 26 (23.2) | <0.001a |
| ≥ 5 | 1 (1.6) | 7 (8.2) | 26 (40.6) | 20 (17.9) | |
| Unknown | 1 (1.6) | 3 (3.5) | 6 (9.4) | 52 (46.4) | |
| Node Status | |||||
| Positive | 1 (1.6) | 40 (47.1) | 52 (81.3) | 22 (19.6) | <0.001a |
| Negative | 59 (93.6) | 31 (36.5) | 5 (7.8) | 0 | |
| Unknown | 3 (4.8) | 14 (16.5) | 7 (10.9) | 90 (80.4) | |
| Nodes Examined | <0.001a | ||||
| 0 | 2 (3.2) | 10 (11.8) | 2 (3.1) | 82 (73.2) | |
| 1-5 | 47 (74.6) | 29 (34.1) | 6 (9.4) | 10 (8.9) | |
| >5 | 10 (15.8) | 41 (48.2) | 50 (78.1) | 12 (10.7) | |
| Unknown | 4 (6.3) | 5 (5.9) | 6 (9.4) | 8 (7.1) | |
| ER status | |||||
| ER + | 55 (87.3) | 70 (82.4) | 47 (73.4) | 81 (72.3) | 0.13a |
| ER− | 6 (9.5) | 13 (15.3) | 15 (23.4) | 12 (10.7) | |
| Unknown | 2 (3.2) | 2 (2.3) | 2 (3.1) | 19 (17.0) | |
| Endocrine Therapy for ER+ Patients (n=253) | |||||
| Yes | 43 (78.2) | 51 (72.9) | 30 (63.8) | 41 (50.6) | 0.001 |
| No/Unknown | 12 (21.8) | 19 (27.1) | 17 (36.2) | 40 (49.4) | |
| Operation | |||||
| Lumpectomy | 43 (68.3) | 39 (45.9) | 14 (21.9) | 3 (2.7) | |
| Mastectomy | 19 (30.2) | 36 (42.4) | 43 (67.2) | 10 (8.9) | <0.001a |
| None | 1 (1.6) | 10 (11.8) | 7 (10.9) | 98 (87.5) | |
| Unknown | 0 | 0 | 0 | 1 (0.9) | |
| Radiation Therapy | |||||
| Yes | 36 (57.1) | 33 (38.8) | 37 (57.8) | 26 (23.2) | <0.001a |
| No | 27 (42.9) | 51 (60.0) | 25 (3.9) | 85 (75.9) | |
| Unknown | 0 | 1 (1.2) | 2 (3.1) | 1 (0.9) | |
| Chemotherapy | |||||
| Yes | 13 (20.6) | 36 (42.3) | 56 (87.5) | 58 (51.8) | <0.001a |
| No | 48 (76.2) | 47 (55.3) | 6 (9.4) | 53 (47.3) | |
| Unknown | 2 (3.2) | 2 (2.4) | 2 (3.1) | 1 (0.9) | |
| Immunotherapy | |||||
| Yes | 3 (4.8) | 1 (1.2) | 4 (6.3) | 5 (4.5) | 0.43a |
| No | 59 (93.6) | 81 (95.3) | 57 (89.1) | 106 (94.6) | |
| Unknown | 1 (1.6) | 3 (3.5) | 3 (4.7) | 1 (0.9) | |
| Survival at last follow-up | |||||
| Alive | 48 (76.2) | 47 (55.3) | 38 (59.4) | 17 (15.2) | |
| Deceased | 13 (20.6) | 27 (31.8) | 22 (34.4) | 87 (77.7) | <0.001 |
a)
Key: p-value based upon excluding unknowns, ER=estrogen receptor, PR=progesterone receptor, CCC=community cancer center, INCC=integrated network cancer center